TUDCA Supplement

## What is TUDCA? Tauroursodeoxycholic acid (TUDCA) is a bile acid produced by conjugating ursodeoxycholic acid (UDCA) with taurine. UDCA is one of the secondary bile acids produced by gut bacteria from primary bile acids; in humans it represents only a few percent of the total bile-acid pool, but it has been used as a pharmaceutical for decades to treat cholestasis, primary biliary cholangitis, and gallstone dissolution. TUDCA is the taurine-conjugated form, which is more water-soluble and crosses the gut wall and the blood-brain barrier more readily than the unconjugated parent molecule. TUDCA has been used in traditional Chinese medicine for centuries as an extract from bear bile. The modern pharmaceutical interest dates to the 1970s and 1980s, when European clinicians began testing it for the same indications as UDCA. It is approved as a pharmaceutical in several countries (Italy under the brand name Tauro, China and others) but in the US it is sold as a dietary supplement rather than as a regulated drug. Supplement marketing has focused on liver protection, mitochondrial function, ER-stress-related conditions, and emerging neurodegenerative applications (ALS, retinitis pigmentosa). The clinical evidence is uneven across these claims: cholestasis and bile-flow indications have decades of trial data; ER-stress and neurological indications have smaller modern trials with promising signals. Legal status: dietary supplement in the US, EU (most countries), and Asia. Not a controlled substance. WADA does not list it. ## Mechanism of action TUDCA's mechanisms span three connected biological roles: **Bile-acid signaling**: TUDCA modulates the FXR (farnesoid X receptor) and TGR5 nuclear receptors in liver and gut, regulating bile-acid synthesis, lipid metabolism, and intestinal barrier function. Unlike many bile acids that activate FXR strongly, TUDCA has a milder receptor effect, which contributes to its tolerability. **ER stress reduction**: TUDCA is a chemical chaperone that stabilizes misfolded proteins in the endoplasmic reticulum and reduces the unfolded protein response (UPR). This is the mechanistic case for its emerging applications in ALS (where misfolded SOD1 and TDP-43 drive motor neuron death), retinitis pigmentosa (rhodopsin misfolding), and metabolic conditions characterized by ER-stress-driven beta-cell dysfunction. **Mitochondrial protection**: TUDCA reduces mitochondrial outer-membrane permeabilization, blocks cytochrome c release, and dampens apoptosis signaling. The mitochondrial case is the strongest preclinical signal for its longevity-supplement positioning. Pharmacokinetics: oral TUDCA reaches plasma within 1 to 2 hours; bioavailability is ~30 to 50% depending on formulation. The compound enters the enterohepatic circulation, increasing total bile-acid pool transiently. Plasma half-life is short (1 to 4 hours); enterohepatic recycling extends functional duration. ## Evidence base by outcome ### Cholestasis and primary biliary cholangitis A-tier in the established UDCA literature; B-tier for TUDCA specifically. Crosignani 1996 and other early Italian trials demonstrated TUDCA reduced cholestasis markers (bilirubin, alkaline phosphatase) at 500 to 750 mg/day in PBC patients, comparable to UDCA. The pharmacological case is settled. ### Non-alcoholic fatty liver disease (NAFLD) C-tier. Several small trials have reported modest improvements in liver enzymes and steatosis markers at 500 to 1,000 mg/day for 12 to 24 weeks. The trials are small and effect sizes modest; comparison with lifestyle intervention is unfavorable. ### Drug-induced liver injury B-tier. Used clinically (off-label in many countries, on-label in others) to support liver recovery from hepatotoxic drug exposure. Evidence is supportive but lacks large modern RCTs. ### ALS (amyotrophic lateral sclerosis) B-tier. Elia 2016 (n=34, single-center) reported reduced ALS Functional Rating Scale decline at 1,000 mg/day TUDCA. The TUDCA-ALS multicenter RCT (Vang 2014 protocol) reported on a phenylbutyrate + TUDCA combination (AMX0035) showing slowed disease progression in CENTAUR (Paganoni 2020) and was approved by FDA as Relyvrio in 2022, though confirmatory trials returned mixed results in 2024 and the drug was withdrawn pending re-review. The pure-TUDCA case in ALS rests on the Elia 2016 trial and supportive preclinical work. ### Retinitis pigmentosa and retinal disease C-tier. Mouse models show clear preservation of photoreceptor function on chronic TUDCA. Small human trials in retinitis pigmentosa report stabilization of visual fields. Effect sizes are modest; the case is strongest as adjunctive therapy. ### Insulin sensitivity and metabolic health C-tier. Small trials report modest improvements in insulin sensitivity in obese non-diabetic adults at 1,750 mg/day for 4 weeks (Kars 2010). The mechanistic case (ER-stress reduction in beta cells and adipocytes) is plausible. Effect sizes are small relative to lifestyle interventions. ### Cognitive function and neurological D-tier in healthy adults. Mechanistic case is plausible (BBB-crossing, ER-stress modulation). No human trial in healthy adults has reported cognitive endpoints. ### Mitochondrial function and longevity C-tier. Mouse studies show preserved mitochondrial function in aging tissues with chronic TUDCA. No human longevity-endpoint trial exists. ### Belly fat and body composition No direct evidence. Trials reporting metabolic improvements (insulin sensitivity, liver fat) have not shown weight or body composition changes. The 'belly fat' marketing claim is not supported by trial data. ## Dosage and administration Most-studied dose ranges: - **Liver / cholestasis indications**: 500 to 750 mg/day, divided into 2 doses, 12 to 24 weeks for clinical effect on liver enzymes - **Metabolic / insulin sensitivity (Kars 2010 protocol)**: 1,750 mg/day for 4 weeks (research dose; not typical for chronic use) - **ALS adjunct (Elia 2016)**: 1,000 mg/day for 12+ months - **Daily supplement use**: 250 to 500 mg/day, often paired with food TUDCA is taken with food to improve tolerability; an empty stomach can produce more GI side effects. Splitting the daily dose into 2 administrations is the common pattern. No cycling protocol is established. Continuous dosing has been used for years in the cholestasis literature without tolerance development. For supplement use, periodic 2 to 4 week breaks are reasonable but not evidence-based. ## Side effects and safety Safety profile is favorable in trials of up to 24 months at therapeutic doses. The most common side effects are mild GI: diarrhea (5 to 10% of users at higher doses), constipation, nausea. These are dose-dependent and resolve with dose reduction. Long-term safety at supplement doses (250 to 500 mg/day) is well-established by extension from the cholestasis literature. Doses above 1,500 mg/day chronically have not been characterized in healthy adults. Drug interactions are minimal at supplement doses. TUDCA may modestly affect absorption of fat-soluble drugs (cyclosporine, oral contraceptives) by altering bile-acid pool composition. The clinical relevance is small at supplement doses; users on critical medications should consult their prescriber. Pregnancy and lactation: insufficient data for routine supplement use. UDCA (the parent compound) is used in cholestasis of pregnancy and has been considered safe in that context; TUDCA-specific data are limited. ## Stack interactions and timing TUDCA stacks reasonably with NAC (additive liver support through different mechanisms), milk thistle (silymarin, a different antioxidant pathway), phosphatidylcholine, and vitamin D. The combinatorial evidence is empirical; controlled-trial data on combinations is sparse. For users targeting metabolic effects, pairing TUDCA with intermittent fasting or time-restricted eating is mechanistically aligned: both reduce ER stress through different routes. No trial has tested the combination. Morning or evening dosing is acceptable. With-food dosing is standard. ## Practical notes Quality varies. Pharmaceutical-grade TUDCA (synthesized from UDCA) is the highest-quality source; bear-bile-derived products are ethically problematic and inconsistent in purity. Look for products specifying synthetic origin and providing a Certificate of Analysis. Cost is moderate. TUDCA runs roughly 30 to 80 cents per 250 mg, making 500 to 1,000 mg/day a 1 to 3 dollar daily expense. Storage matters. The compound is stable at room temperature in dry conditions; refrigeration is not required. For the use case: TUDCA has the strongest evidence base in cholestasis (where it is used as a pharmaceutical in several countries) and ALS adjunctive therapy. Liver-supplement marketing rests on real but modest effects. The longevity / mitochondrial positioning is mechanistically defensible but lacks human outcome trials. Users buying TUDCA for general 'liver support' or longevity are making a reasonable bet on a well-tolerated compound with a good safety record; users with diagnosed liver disease should run the decision through a hepatologist.